IPsoft Equips Businesses to Accelerate Digital Transformation at Scale by Automating Delivery of Enterprise Services with 1Desk(TM)
1Desk(TM), the world's first AI platform to combine cognitive and autonomic technologies, will fully automate shared enterprise services
NEW YORK, Nov. 07, 2017 (GLOBE NEWSWIRE) -- IPsoft, the leader in enterprise AI, today announced its visionary new platform for business users, 1Desk(TM), that enables businesses to accelerate digital transformation and stay competitive in the digital economy. For the first time, enterprises will be able to draw on a digital labor pool of cognitive agents, virtual engineers and virtual administrators in order to automate entire end-to-end processes, from HR and IT, to Finance and Administration. Employees will no longer have to navigate multiple systems but instead channel all their requests and queries through a single cognitively-enabled interface to access a full suite of enterprise services 24-by-7.
Although the average cost of Selling, General and Administrative (SG&A) expenses across industries sits at around 25% of sales1, this can be considerably higher in major industries including Financial Services (41%) and Healthcare (38%). The level of automation made possible by 1Desk(TM) could cut this to a fraction of the cost. At the same time, employee productivity is set to rise sharply as dedicated personal digital support will eliminate the time wasted by filling out cumbersome forms and waiting for routine tasks to be completed.
"1Desk(TM) is the unified service desk that converges the front and back offices. It directly connects business users to the applications that service them, disintermediating large segments of IT and business operations. 1Desk(TM) improves the Net Promoter Scores not only for IT, but for HR, finance, helpdesk, facilities and administrative tasks. The big difference to 1Desk(TM) is that it has cognitive competence so it can understand business users directly, and service their requests through automated digital labor, not by armies of people," said Chetan Dube, CEO of IPsoft.
Uniquely, 1Desk(TM) will be able to target the inefficiencies that lie in processes running across different functions. For example, the comprehensive process knowledge capabilities of Amelia, IPsoft's market-leading cognitive agent embedded in the 1Desk(TM) platform, can act as the glue to unify the implications of policy changes across all supporting enterprise systems by automatically updating intelligent workflows.
In the $6.3 trillion2 race for digital renovation, manual processes have become a stumbling block for operational efficiency and market growth. Static point solutions that automate single steps in the process limit the speed of change that is required to compete with companies that were 'born-digital' as well as traditional competitors that are on a fast track to digital adoption. Through machine learning, 1Desk(TM) facilitates rapid improvement and industrializes a cycle of continuous improvement and learning from every interaction with business users. Exceptions that are managed by human engineers and administrators within 1Desk(TM) are recorded at all times so that a stream of new intelligent automation is generated, speeding up the ability to implement new efficiencies going forward.
Carestream Health, a global provider of medical imaging systems and IT solutions, will be the first Beta customer for 1Desk(TM). "1Desk(TM) introduces AI innovation on a grand scale, opening up the possibility to set a new standard for cognitive-enabled business processes in terms of both speed and quality," said Gerson Benker, Vice President of IT Operations at Carestream. "We are excited at the prospect of employing 1Desk(TM)'s end-to-end automation capabilities within our strategy in order to provide an even better experience for our business users and customers."
The vastly increased automation of business processes enabled by 1Desk(TM) represents a radical shift in the operating model for enterprise organizational models. In the future, the execution of tasks will be predominantly fulfilled by Digital Labor. Human talent will focus on managing and directing the further development of automation. IPsoft facilitates the creation of a Digital Labor Studio within organizations to orchestrate the rapid development of a continuously improving Digital Workforce. This unique hub of digital enablement talent will coordinate the work of automation engineers, data scientists, linguists, business analysts, user-experience designers and system integrators to deliver on the full value of 1Desk(TM).
1Desk(TM) is created on a foundation of market-leading technology. Amelia is widely recognized as being at the forefront of conversational AI platforms and was recently described by industry analyst firm Ovum as being uniquely suitable for enabling entirely new customer channels. IPsoft's autonomic technology has been spearheading transformation at scale for more than 15 years and is noted by research analyst Everest Group as the leader in IT automation.
IPsoft, the leader in enterprise AI, automates IT and business processes for enterprises across a wide range of industries by deploying Digital Labor. Through its portfolio of world leading autonomic and cognitive solutions, IPsoft provides services that allow its clients to secure competitive advantage. Headquartered in New York City, IPsoft has 18 offices in 15 countries across the world and serves more than 500 of the world's leading brands directly as well as more than half of the world's largest IT services providers.
Daniela Zuin, +1 212 708 5521
Marketing Director, IPsoft
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: IPsoft via Globenewswire
Följ NASDAQ OMX
Abonnera på våra pressmeddelanden.
Senaste pressmeddelandena från NASDAQ OMX
Standard Lithium Announces Closing of $21.6 million Bought Deal Private Placement of Units16.2.2018 19:25 | Pressmeddelande
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. VANCOUVER, British Columbia, Feb. 16, 2018 (GLOBE NEWSWIRE) -- Standard Lithium Ltd. ("Standard Lithium" or the "Company") (TSX-V:SLL) (OTCQX:STLHF) (FRA:S5L) announced today that it has closed its previously announced bought deal private placement of 10,312,821 units of the Company (the "Units"), at a price of $2.10 per Unit, for aggregate gross proceeds to the Company of $21,656,924, including the issuance and sale of the Underwriters' (as defined below) option (the "Offering"). Each Unit consists of one common share of the Company and one-half of one common share purchase warrant (each whole common share purchase warrant, a "Warrant"). Each Warrant is exercisable to acquire one common share of the Company (a "Warrant Share") until February 16, 2020 at an exercise price of $2.60 per Warrant Share, subject to adjus
Cisco Offers Cloud-Based Endpoint Security Solutions for Managed Security Service Providers16.2.2018 14:00 | Pressmeddelande
Cisco's comprehensive cloud-based security endpoint portfolio provides advanced malware protection, internet security, and enterprise mobility management SAN JOSE, Calif., Feb. 16, 2018 (GLOBE NEWSWIRE) -- Cisco today is helping address the challenges of Managed Security Service Providers (MSSP) and their customers by offering MSSPs comprehensive security, visibility, and control of customer endpoints without added hardware or complexity. The Cisco endpoint security portfolio includes three industry-leading solutions-Cisco AMP for Endpoints, Cisco Umbrella, and Meraki Systems Manager to offer protection against advanced malware and threats. Security teams know the endpoints in their environments are being targeted by advanced threats, but often lack the security talent, tools, and budget to address those challenges. As a result, organizations of all sizes are choosing to augment their in-house IT security with managed security services. Nearly half of SMBs and enterprises in the US1 ar
Aurora Solar Adds Heterojunction Cell Characterization to Decima Gemini Family16.2.2018 14:00 | Pressmeddelande
Aurora Solar Technologies Inc. / Aurora Solar Adds Heterojunction Cell Characterization to Decima Gemini Family . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement. NORTH VANCOUVER, British Columbia, Feb. 16, 2018 (GLOBE NEWSWIRE) -- Aurora Solar Technologies Inc. ("Aurora") ("Company") (TSX.V:ACU) (OTCBB:AACTF) (FSE:A82) is pleased to provide an update on the further development of its Decima Gemini(TM) infrared measurement technology for applications in the rapidly developing heterojunction (HJT) cell manufacturing market. HJT is an ultra high-efficiency solar cell design pioneered by Japan's Panasonic Corp., who is now also partnered with Tesla Inc. for solar products. According to Solar Media Ltd., HJT production capacity is expected to increase by 20 percent this year. To produce the electrical structure of a HJT cell, it is necessary to apply thin layers of amorphous silicon on both sides of a crystallin
Nasdaq Cited as a Leader in Governance, Risk, and Compliance Platforms by Independent Research Firm16.2.2018 13:35 | Pressmeddelande
NEW YORK, Feb. 16, 2018 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq:NDAQ) was among the select companies that Forrester invited to participate in its 2018 Forrester Wave(TM) evaluation, Governance, Risk, And Compliance (GRC) Platforms, Q1 2018. In this evaluation, Nasdaq was cited as a Leader in Governance, Risk, and Compliance Platforms and received the maximum score of 5 for the evaluation criteria "Risk & Control Management", "Audit Management", "Dashboard and Reporting" and "Integration capabilities" for its BWise solutions. "We feel the strong scores we obtained in important functional areas provide assurance to our clients that they have selected a robust and future-proof software platform," said Tom Passon, Head of Product Innovation & Global Standards, Nasdaq BWise. "We are proud of this recognition that encourages us to further execute on our strategy to provide user-friendly, pre-configured best practice solutions that combine our innovative GRC software platform with leading expertis
Mandalay Resources Provides Target Release Date for Fourth Quarter and Full-Year 2017 Financial Results and Conference Call16.2.2018 13:30 | Pressmeddelande
TORONTO, Feb. 16, 2018 (GLOBE NEWSWIRE) -- Mandalay Resources Corporation ("Mandalay" or "the Company") (TSX:MND) today announced that its fourth quarter and full-year 2017 financial results will be released after market close on February 21, 2018, followed by a conference call with Mark Sander, President and Chief Executive Officer of Mandalay, for investors and analysts on February 22, 2018 at 8:00 am (Toronto time). Analysts and interested investors are invited to participate using the following dial-in numbers: Participant Number: (201) 689-8341 Participant Number (Toll free): (877) 407-8289 Conference ID: 13676606 A replay of the conference call will be available until 11:59 pm (Toronto time), March 8, 2018 and can be accessed using the following dial-in number: Encore Toll Free Dial-in Number: (877) 660-6853 Encore ID: 13676606 For Further Information: Mark Sander President and Chief Executive Officer Greg DiTomaso Director of Investor Relations Contact: +1.647.260.1566 About Man
Apricus Biosciences Receives Complete Response Letter from FDA for Vitaros(TM)16.2.2018 13:00 | Pressmeddelande
Company Evaluating Deficiencies and Potential Path Forward SAN DIEGO, Feb. 16, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that the U.S. Food and Drug Administration ("FDA") has issued a complete response letter ("CRL") for the New Drug Application ("NDA") of Vitaros(TM) (alprostadil, DDAIP.HCl), a topical cream for the treatment of erectile dysfunction. The CRL indicates that the FDA cannot approve the NDA for Vitaros in its present form, identifying deficiencies related to Chemistry, Manufacturing and Control ("CMC") and certain safety concerns specific to the 2.5% concentration of DDAIP.HCl contained in the current formulation. "We are disappointed with the outcome of the review given the substantial amount of CMC, clinical and non-clinical data and analysis provided to the FDA in the Vitaros resubmission. We are assessing the content of the complete response
I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.Besök vårt pressrum